GlassScriptPhysician profile
Savannah R Prantil
NPI 1790391746
$2,134.00
in general payments reported to CMS, 2019-2025
29 companies · $77.79 in 2025
The $77.79 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $249 · 2023: $414 · 2024: $910 · 2025: $77.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102 · Travel and Lodging: $281 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.14 |
| Travel and Lodging | $281.00 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $281.00 | 2024 | |
| Abbvie INC. | $251.35 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $218.03 | 2022-2025 | |
| Eisai INC. | $133.40 | 2021-2024 | |
| Sk Life Science, INC. | $128.66 | 2023-2024 | |
| Medtronic, INC. | $122.00 | 2023-2024 | Corevalve Evolut R, Duet |
| Takeda Pharmaceuticals U.S.A., INC. | $97.27 | 2023-2024 | Hyqvia, Gammagard |
| Abbott Laboratories | $91.80 | 2024 | Mitraclip |
| Alexion Pharmaceuticals, INC. | $89.39 | 2021-2024 | Ultomiris |
| Neurocrine Biosciences, INC. | $68.29 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $68.12 | 2023-2024 | Xeomin |
| Kyowa Kirin, INC. | $65.55 | 2021 | |
| Csl Behring | $56.82 | 2021 | |
| Jazz Pharmaceuticals INC. | $53.53 | 2021-2022 | |
| Grifols USA, LLC | $49.50 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $49.48 | 2021 | |
| Ucb, INC. | $39.82 | 2023-2024 | Rystiggo |
| Biogen, INC. | $39.00 | 2023-2024 | Vumerity, Plegridy, Avonex |
| Lilly USA, LLC | $37.27 | 2024 | Amyvid |
| Irhythm Technologies, INC. | $34.21 | 2024 | Zio Xt Patch, Zio Monitor |
| Depuy Synthes Sales INC. | $31.00 | 2021 | |
| Silk Road Medical, INC. | $22.73 | 2022 | |
| Amgen INC. | $22.22 | 2021 | |
| Argenx US, INC. | $15.25 | 2023 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $14.95 | 2021 | |
| Sumitomo Pharma America, INC. | $14.43 | 2023 | Aptiom |
| Inspire Medical Systems, INC. | $14.18 | 2024 | Inspire |
| Amneal Pharmaceuticals LLC | $13.05 | 2021 | |
| Ge Healthcare | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savannah Prantil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.